Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935550 | 1.00 | HTT (0.53) | HTTKDM4ELMNARECQLKMT2A | |
| SCHEMBL5867088 | 0.82 | CBR1 (0.44) | HTTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL5867078 | 0.82 | CBR1 (0.44) | HTTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL5866830 | 0.80 | CBR1 (0.45) | HTTKDM4ELMNAKMT2AALDH1A1 | |
| SCHEMBL5866832 | 0.80 | CBR1 (0.45) | HTTKDM4ELMNAKMT2AALDH1A1 | |
| SCHEMBL5866855 | 0.79 | MAOB (0.60) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL5866852 | 0.79 | MAOB (0.60) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL5867011 | 0.78 | CTPS1 (0.42) | HTTKDM4ELMNARECQLKMT2A | |
| SCHEMBL5935553 | 0.77 | LMNA (0.53) | HTTKDM4ELMNARECQLKMT2A | |
| SCHEMBL5866940 | 0.77 | KCNQ2 (0.46) | HTTKDM4ELMNARECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148259-B1 | Antibacterial agents | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | AMGEN INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-6780858-B2 | Antibacterial agents | TULARIK INC. | 2004-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | MRPL21, HDHD5, CLPP | HTT 638/4885KDM4E 4511/4885LMNA 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.